Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-25T06:08:17.325Z Has data issue: false hasContentIssue false
  • English
  • Français

Antinuclear antibodies in schizophrenia and major depressive disorder — a lasting puzzle

Published online by Cambridge University Press:  16 April 2020

K Schott ,
A Uhl ,
A Batra ,
M Bartels ,
B Eusterschulte  and
G Buchkremer
K Schott
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Osianderstrasse 22, D-72076Tübingen, Germany
A Uhl
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Osianderstrasse 22, D-72076Tübingen, Germany
A Batra
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Osianderstrasse 22, D-72076Tübingen, Germany
M Bartels
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Osianderstrasse 22, D-72076Tübingen, Germany
B Eusterschulte
Affiliation:
Fachklinik Rottenmünster, Schwenningerstrasse 35, D-78628Rottweil, Germany
G Buchkremer
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Osianderstrasse 22, D-72076Tübingen, Germany
Get access

Summary

Sera from patients with major depressive disorder and paranoid schizophrenia were screened for antinuclear antibodies (antigens: ds-DNA, ENA, histone H3) and circulating immune complexes (CIC-Cq1) by ELISA. Controls were healthy blood donors. Only a few of the patients' sera were positive for anti-ds-DNA and anti-ENA antibodies. There was no significant result. In paranoid schizophrenia 20.5% of sera were positive for antibodies against histone H3. In the case of CIC-Cql, 7% of the patients with major depressive disorder and 11 % of those with paranoid schizophrenia were positive. Controls showed positive sera in 39%. This study disagrees with former studies which could demonstrate a series of antinuclear antibodies in mental disorders. In the case of antihistone antibodies, the present results could indicate an autoimmune process in a subgroup of schizophrenic patients.

Keywords

antinuclear antibodieshistonesmajor depressive disorderschizophrenia
Type
Short communication
Information
European Psychiatry , Volume 11 , Issue 5 , 1996 , pp. 263 - 267
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alarcon-Segovia, DFischbein, ECetina, JARaya, RJBarrera, EAntigenic specificity of chlorpromazine-induced antinuclear antibodies Clin Exp Immunol 1973; 15: 543–548Google ScholarPubMed
Berglund, SGottfries, CGGottfries, IStormby, KChlorpromazine-induced antinuclear factors Acta Med Scand 1970; 187: 67–74CrossRefGoogle ScholarPubMed
Brauchitsch, HAntinuclear factor in psychiatric disorders Am J Psychiatry 1972; 128: 1552–1554CrossRefGoogle Scholar
Canoso, RTOliveira, RMNixon, RANeuroleptic associated autoantibodies. A prevalence study Biol Psychiatry 1990; 27: 863–870CrossRefGoogle ScholarPubMed
Chengappa, KNRCarpenter, ABYang, ZWBrar, JSRabin, BSGanguli, RElevated IgG antihistone antibodies in a subgroup of medicated schizophrenic patients Schizophrenia Res 1992; 7: 49–54CrossRefGoogle Scholar
Deberdt, RVan Hooren, JBiesbrouck, MAmery, WAAntinuclear factor —positive mental depression: a single disease entity? Biol Psychiatry 1976; 11: 69–74Google ScholarPubMed
Ganguli, RRabin, BSKelly, RHLyte, MRagu, UClinical and laboratory evidence of autoimmunity in acute schizophrenia Ann NY Acad Sci 1987; 496: 676–685CrossRefGoogle ScholarPubMed
Gompertz, NRIsenberg, DATurner, BMCorrelation between clinical features of systemic lupus erythematosus and levels of antihistone antibodies of the IgG, IgA, and IgM isotypes Ann Rheum Dis 1990; 49: 524–527CrossRefGoogle ScholarPubMed
Gottfries, CGGottfries, IAntinuclear factors in relation to age, sex, mental disease and treatment with phenothiazines Acta Psychiatr Scand 1974; 255:(Suppl) 193–201CrossRefGoogle ScholarPubMed
Johnston, ECWhaley, KAntinuclear antibodies in psychiatric illness: their relationship to diagnosis and drug treatment Br Med J 1975; 2: 724–725CrossRefGoogle Scholar
Legros, SMendlewicz, JWybran, JImmunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders Eur Arch Psychiatr Neurol Sci 1985; 235: 9–11CrossRefGoogle ScholarPubMed
Maes, MBosmans, ESuy, EVandervorst, CDejonckheere, CRaus, JAntiphospholipid, antinuclear, Epstein-Bar and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients J Affective Dis 1991; 21: 133–140CrossRefGoogle Scholar
Sirota, PFirer, MASchild, KTanay, AElizure, AMeytes, DSlor, HAutoantibodies to DNA in multicase families with schizophrenia Biol Psychiatry 1993; 33: 450–455CrossRefGoogle ScholarPubMed
Spitzer, RLEndicott, JRobins, EResearch diagnostic criteria Arch Gen Psychiatry 1987; 35: 773–782CrossRefGoogle Scholar
Tan, EMAntinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology Adv Immunol 1989; 44: 93–151CrossRefGoogle ScholarPubMed
Villemain, FMagnin, MFeuillet-Fieux, MNZarifian, ELoo, HBach, JFAntihistone antibodies in schizophrenia and affective disorders Psychiatry Res 1988; 24: 53–60CrossRefGoogle Scholar
Yannitsi, SGManoussakis, MNMauridis, AK, et al.Factors related to the presence of autoantibodies in patients with chronic mental disorders Biol Psychiatry 1990; 27: 747–756CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.